Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q4 2024 Earnings Presentation
18 slides from Bactiguard Holding Ab's earnings presentation, Feb 6, 2025
Slide 1: Q4 and year-end 2024 presentation
Q4 and year-end 2024 presentation Thursday 6 February 2025 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q4 and year-end 2024 summary
Q4 AND YEAR-END 2024 SUMMARY License focused strategy delivered increased revenues and profitability
Slide 3: Full-year 2024 key figures and highlights
Full-year 2024 key figures and highlights License focused strategy delivered increased revenues and profitability Key figures for 2024 (2023) Highlights • Delivered on strategic shift Revenues 261.9 (223.2) MSEK • Achieved increased revenues and EBITDA profitability EBITDA 18.0 (-76.1) MSEK • Sharpe
Slide 4: Advanced technology to prevent medical device related infections
Advanced technology to prevent medical device related infections Reduces microbial adhesion and biofilm formation • Biocompatible, safe and proven • Ultra-thin noble metal coating technology • In contact with fluids, the noble metals create a galvanic effect due to their varying electro potentials •
Slide 5: The issue of healthcare associated infections
The issue of healthcare associated infections • 1 in 10 patients worldwide affected by healthcare associated infections (HAI)1 • 40-60% of all HAIs caused by medical devices2 • Up to 50% of HAIs estimated to be preventable3 • Costs associated with HAIs (ie extended hospital stays and additional trea
Slide 6: Effective license focused strategy and business model
Effective license focused strategy and business model R&D License Medical Wound Management partnerships portfolio Regulatory Focus ahead Advance current and Deliver competencies to Grow profitably develop future enhance partnerships 6
Slide 7: Strengthened competencies across multiple knowledge areas
Strengthened competencies across multiple knowledge areas • Tanny • Kajsa Nathaniel Bachrach Kajsa Björklund Chief Scientific Officer Executive VP R&D Member of the Executive Management Team Member of the Executive Management Team Brings a wealth of experience from the MedTech Bringing extensive exp
Slide 8: Recap of business model and partner journey
Recap of business model and partner journey Three partnership phases and two main revenue drivers: license fees and royalties 8
Slide 9: BD partnership update
BD partnership update Global partnership approach – BD’s success is Bactiguard’s success • Revenues from BD collaboration main driver of EBITDA and increased license revenues in Q4 and 2024 • Engagement across the entire value chain – from technology to go-to-market • Collaboration on market registr
Slide 10: Zimmer Biomet partnership update
Zimmer Biomet partnership update Trauma collaboration including commercial stage ZNN Bactiguard • Four ongoing clinical trials in Europe* – main study on ZNN Bactiguard (comparative study) • Commercialization of the ZNN Bactiguard trauma nail, especially in Europe • Focus on regulatory processes, in
Slide 11: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections by offering effective, biocompatible solutions to improve wound healing • Continued path of profitable growth for Q4 and 2024 ® VIGIMESH • The Bactiguard Global Wound Care Webinar was broadcast live from London on November 22, 2024. • Successfully
Slide 12: Total revenue Q4 and FY 2024
For the period Oct-Dec: Total revenue Q4 and FY 2024 • Total license revenue amounted to 44.2 (32.2) MSEK • Revenues from BD amounted to 35.8 (29.1) MSEK • Revenues from Zimmer Biomet Oct-Dec Jan-Dec amounted to 3.6 (3.1) MSEK MSEK 2024 2023 2024 2023 • Revenues from Wound Management Total license r
Slide 13: Net sales growth Q4 and FY 2024
Net sales growth Q4 and FY 2024 Net sales Fourth quarter (Oct-Dec) Full-year (Jan-Dec) SEK million +19.9% 241.7 16.0 201.5 30.5 60.9 BIP portfolio 53.8 Wound Management portfolio License revenues +12.1% 63.1 164.7 56.3 3.2 117.2 10.2 15.6 13.9 32.2 44.2 2023 2024 2023 2024 13 Source: Bactiguard Hold
Slide 14: EBITDA growth Q4 and FY 2024
EBITDA growth Q4 and FY 2024 EBITDA Fourth quarter (Oct-Dec) Full-year (Jan-Dec) SEK million +94.1 +12.7 18.0 8.4 -4.2 EBITDA 2023 2024 -76.1 2023 2024 14 Source: Bactiguard Holding AB, Interim report Q3 2024, p. 17
Slide 15: Total operating expenses and cash flow Q4 and FY 2024
Total operating expenses and cash flow Q4 and FY 2024 Operating expenses Cash flow In Q4: In Q4: • Costs for raw materials and consumables • Cash flow from operating activities amounted amounted to -5.9 (-15.7) MSEK to 18.9 (10.1) MSEK • Other external costs amounted to -21.7 • Cash flow from invest
Slide 16: Concluding 2024
Concluding 2024 Delivering on the promise of our infection prevention technology • Delivered increased revenues and achieved profitability • Delivered on strategic shift • Technology is effective and we see increased interest from potential partners • Effectiveness of license focused strategy and bu
Slide 17: Q&A
Q&A to champion a healthier world by preventing infections
Slide 18: Questions & Answers
Questions & Answers Q4 and year-end 2024 presentation Christine Lind Patrick Bach CEO CFO